Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



The Pharmaceutical Industry needs Pharmacists – How can we move them from behind the counter?

26 Apr 04

There are certainly a variety of challenges available in industry but it often means moving to different parts of the company and uprooting to get that variety.
Mike Breese and Jeff Webb

Merckle demonstrate superior safety of Licofelone the first dual COX/LOX inhibitor: Opportunities for improved osteoarthritis treatment

22 Apr 04

DailyUpdates 22nd April: Phase III studies have previously shown Merkle’s first in the class COX/LOX inhibitor, Licofelone, to be equally effective to standard treatments of osteoarthritis. Moreover, gastrointestinal adverse events tended to be less frequent in patients treated with licofelone as compared to naproxen. In this month’s edition of the American Journal of Gastroenterology new data is published showing clear cut advantages of licofelone arising from the dramatic reduction in incide

HU-320 identified as a novel synthetic cannabinoid with therapeutic activity in an experiment model of rheumatoid arthritis

20 Apr 04

DailyUpdates 20th April: An estimated 5 million individuals suffer from rheumatoid arthritis in the Western world. CB1 cannabinoid receptor ligands are in development as candidate treatments of this disease due to their analgesic properties. Now researchers from the Hebrew University and the Kennedy Institute of Rheumatology in London have demonstrated the anti-inflammatory, disease modifying efficacy of the non-psychoactive cannabinoid, HU-320 in a model of rheumatoid arthritis.

NicOx's nitrosulindac (NCX 1102) emerges as a candidate treatment of bladder cancer

19 Apr 04

DailyUpdates 19th April: NSAIDs have shown promising activity in the prevention and possible treatment of cancer. The French pharmaceutical NicOx has successfully improved both the safety and efficacy of NSAIDs by attaching a nitric oxide donor group to various NSAIDs. In a recent study nitrosulindac has been demonstrated to act as an effective and selective cytotoxic and antiproliferative agent against bladder cancer cells. The efficacy of nitrosulindac was considerable better than sulindac.

Gene silence to set to quieten neuropathic pain - Novartis research expands the potential of siRNA

16 Apr 04

DailyUpdates 16th April: RNA interference is emerging as a major tool to help researchers identify new therapeutic targets. Novartis researchers have recently used this technology to underline the role that the ligand activated cation-channel, P2X3 plays in neuropathic pain. This study also demonstrates the therapeutic potential of P2X3 gene silencing in the treatment of this major unmet area of analgesia.

Prodrugs: Effective Solutions for Solubility, Permeability, and Targeting Challenges

16 Apr 04

Pharmaceutical Education Associates is proud to present: The Inaugural Prodrugs: Effective Solutions for Solubility, Permeability, and Targeting Challenges Conference, June 28-29, 2004 at The Union League, Philadelphia, PA. . Please visit for more details, or call 800-686-2276.
Jennifer McGinnis

Paclitexel-induced neuropathic pain - McGill study may lead to the identification of novel targets for analgesia and improved cancer therapeutics

14 Apr 04

DailyUpdates 14th April: Neuropathic pain affects 26 million patients including a sub-population of cancer patients being treated with cytotoxics. McGill researchers have published the results of a study looking at neuropathic pain in various strains of mice. These data show that neuropathic pain has a genetic component suggested to be equally relevant to paclitaxel and surgically-induced pain. The study also advances the use of paclitaxel-induced hyperalgesia as a model for the development o

Novo Nordisk publish data demonstrating proof of concept for potassium channel openers as treatments of diabetes

13 Apr 04

DailyUpdates 13th April: According to WHO, there are some 130 million diagnosed diabetics in the world, a figure that is predicted to increase to 300 million by 2025. Approximately 10-15% of these patients suffer type 1 diabetes. Novo Nordisk have shown that their Kir6.2/SUR1 channel opener, NN414 is able to preserve beta-cell function and reduction of insulitis presumable through the induction of "beta-cell rest".

Drug delivery technology predicted to allow safer and more effective use of steroids in the treatment of rheumatoid arthritis

08 Apr 04

DailyUpdates 8th April: An estimated 5 million individuals suffer from rheumatoid arthritis in the Western world. Corticosteroids are the most dramatically effective short-term anti-inflammatory drugs; however, their clinical benefit for rheumatoid arthritis often diminishes with time. This, the severe rebounds observed following the withdrawal of corticosteroids, and long-term systemic side effects associated with corticosteroids limits their use in the treatment of rheumatoid arthritis. Rese

Eli Lilly's Duloxetine set to become the first widely used therapeutic treatment of stress urinary incontinence

07 Apr 04

DailyUpdates 7th April: A recent survey of community-dwelling women in France, Germany, Spain and the UK found that 35% women suffer urinary incontinence, the most prevalent form of which was stress urinary incontinence. The findings also revealed that two-thirds of women affected with urinary incontinence never consulted a health care professional for treatment. The perceived and real lack of pharmaceutical options for the treatment of stress urinary incontinence is a major factor contributing

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.